Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228265 | 0.98 | EPHX1 (0.45) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL801082 | 0.95 | EPHX1 (0.38) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL15043696 | 0.93 | EPHX1 (0.36) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL888752 | 0.90 | — | — | |
| Thiophene SCHEMBL27504247 | 0.85 | HPGD (0.35) | KMT2AEPHX1HPGDL3MBTL1NPC1 | |
| SCHEMBL26296878 | 0.84 | EPHX1 (0.45) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| Thiophene SCHEMBL27561996 | 0.84 | HPGD (0.38) | KMT2AEPHX1HPGDL3MBTL1NPC1 | |
| SCHEMBL27437036 | 0.83 | KMT2A (0.41) | KMT2AEPHX1HPGDL3MBTL1NPC1 | |
| SCHEMBL27437382 | 0.83 | KMT2A (0.37) | KMT2AEPHX1HPGDSLC1A3SLC1A2 | |
| SCHEMBL16233037 | 0.82 | SHBG (0.35) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129963-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024003535-A2 | COMPOUNDS | UNIVERSITY OF DUNDEE (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023196458-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| WO-2008028057-A2 | SHIKIMIC ACID-DERIVED COMPOUNDS FOR INHIBITION AND DETECTION OF AURORA A-ASSOCIATED TUMORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2003065987-A2 | GRANZYME B INHIBITORS | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | KMT2A 4798/4885EPHX1 4155/4885HPGD 2610/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | KMT2A 3449/4885EPHX1 1446/4885HPGD 2426/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | KMT2A 2807/4885EPHX1 2260/4885HPGD 570/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | KMT2A 415/4885EPHX1 4053/4885HPGD 4729/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | KMT2A 2807/4885EPHX1 2260/4885HPGD 570/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | KMT2A 2807/4885EPHX1 2260/4885HPGD 570/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | KMT2A 2836/4885EPHX1 778/4885HPGD 907/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | KMT2A 2609/4885EPHX1 681/4885HPGD 478/4885 |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | KMT2A 4798/4885EPHX1 4155/4885HPGD 2610/4885 |
| US-20210009594-A1 | 5-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | KMT2A 4818/4885EPHX1 1120/4885HPGD 2473/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | KMT2A 3449/4885EPHX1 1446/4885HPGD 2426/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | KMT2A 2491/4885EPHX1 793/4885HPGD 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.